中國抗體製藥有限公司

SinoMab BioScience Limited

(Incorporated in Hong Kong with limited liability)

(Stock Code: 3681)

SinoMab Completed Patient Enrollment in Phase 1b Clinical Trial

(9 December 2024 – Hong Kong), A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialisation of therapeutics for the treatment of immunological diseases- **SinoMab BioScience Limited ("SinoMab" or the "Company"; Stock Code: 3681)**, is pleased to announce that, on 4 December 2024, the enrollment of 32 patients have been completed for the phase 1b clinical trial of SM17 for the treatment of moderate to severe Atopic Dermatitis ("**AD**") patients in China.

The Phase 1b clinical trial is a randomized, double-blind, placebo-controlled study designed to study safety, tolerability and pharmacokinetics (PK) profiles of SM17, as well as to evaluate the preliminary efficacy of SM17 in adult patients with moderate to severe AD.

The first patient was dosed in the phase 1b clinical trial on 11 June 2024, and the last subject last visit (LSLV) is scheduled to be completed by the end of March 2025. We expect to have the topline data available in the first quarter of 2025. The Company had conducted phase I clinical study in the US and China, clinical reports revealed a good safety profile, tolerability and PK of SM17 with no drug-related serious adverse event (SAE) reported; the safety results and PK profile are consistent in both Asian population and Caucasian population. The Company published the preclinical paper of SM17 on *Allergy*, an official journal of the European Academy of Allergy and Clinical Immunology (EAACI), in April 2024. The study showed that the therapeutic efficacy of SM17 is comparable to that of JAK1 inhibitor in treating animals with AD.

SM17 is a novel, First-in-Class (FIC), humanized, IgG4-κ monoclonal antibody, which is a global first-in-class monoclonal antibody drug targeting IL-25 receptor with the potential for treating AD, asthma, idiopathic pulmonary fibrosis and other immunological disorders. SM17 could suppress Type 2 helper T (Th2) immune responses by binding to IL-25 receptor (also known as IL-17RB) on Type 2 Innate Lymphoid cells (ILC2s) and Th2 cells, to block a cascade of responses induced by IL-25 and suppress the release of the downstream Th2 cytokines such as IL-4, IL-5 and IL-13. IL-25 is a critical cytokine classified as ''alarmin'', which has shown to be implicated in the pathogenesis of autoimmune and inflammatory skin diseases, especially in AD. Current approved therapies for AD, including biologics, can significantly improve eczema area and severity index (EASI) and patient's quality of life, but they either are slow in response, especially in anti-pruritic effect, or have safety concerns. With the novel mechanism of action, SM17 hopefully will become a new and probably better treatment option for AD, which is fast in anti-pruritic response, effective in skin healing and safe, addressing the unmet medical needs not covered by current treatment modalities.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab, said, "The clinical study of SM17 has been progressing as planned. We are confident the Phase 1 clinical trial topline results to be obtained in the first quarter of 2025 could reveal SM17 as a safe and fast-acting biologic in relieving pruritus and improving skin healing in patients with moderate to severe AD. It is estimated over 200 million people globally are affected with AD, of which one third are considered moderate to severe. Being a first-in-class product with potentially differentiating therapeutic efficacies and safety, the Company is confident in the huge development prospects of SM17 in the treatment of AD. Moreover, the novel mechanism of action of SM17 has also demonstrated therapeutic potential in other indications, such as asthma and idiopathic pulmonary fibrosis (IPF), the Company will also initiate research into these indications in the future. In addition to continuing to develop independently of our product pipeline, we are also committed to exploring and searching for partners to collaborate on the development of other innovative therapeutics to address unmet medical needs in the field of immune diseases, thereby benefiting more patients and communities."

- End -

About SinoMab BioScience Limited

SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. SinoMab is headquartered in Hong Kong with its R&D base in Hong Kong and production base in mainland China. The Company's flagship product Suciraslimab (SM03) is a potential global first-in-class mAb against CD22 for the treatment of rheumatoid arthritis (RA) and other immunological diseases. SM03 (Suciraslimab) has completed the Phase III clinical trial for RA in China and is pending NMPA's marketing approval for RA in China. In addition, the Company possesses other potential first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Sjogren's syndrome (SS), systemic lupus erythematosus (SLE), atopic dermatitis (AD), idiopathic pulmonary fibrosis (IPF), asthma, and other diseases with major unmet clinical needs.

Media enquiries

Strategic Financial Relations Limited

Veron Ng	Tel: +852 2864 4831	Email: veron.ng@sprg.com.hk
Phoenix Fung	Tel: +852 2114 4939	Email: phoenix.fung@sprg.com.hk
Shannon Lei	Tel: +852 2114 2881	Email: shannon.lei@sprg.com.hk
Will Cheng	Tel: +852 2864 4894	Email: will.cheng@sprg.com.hk